Biogen Pharmachem Industries L
BSE: BIOGEN · Other Financial Services · sector
Key numbers
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 96 companies in Other Financial Services (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹0 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Net loss in 2 of the last 6 quarters.
- No dividend in the last 5 financial years.
- Price ₹0.24 on 2026-10-26: -71.8% from the 52-week high, 0.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 1 | 2 | 0 | 0 | 1 | 0 |
| EBITDA | 1 | 1 | -0 | -0 | -0 | 0 |
| OPM % | 87.4% | 87.0% | – | – | -62.1% | 50.0% |
| Other income | 0 | 0 | -0 | 1 | 0 | 0 |
| Net profit | 1 | 1 | -0 | 0 | -0 | 0 |
| EPS (₹) | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Revenue YoY | -57.0% | -71.4% | ||||
| Profit YoY | -130.5% | -83.6% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 2 | 1 | – | 1 | 3 | 1 |
| EBITDA | -0 | 0 | -0 | -0 | 1 | -1 |
| Net profit | -0 | 0 | 2 | -0 | 1 | -0 |
| EPS (₹) | – | 0.01 | 0.03 | 0.00 | 0.01 | 0.02 |
| Revenue growth | -61.6% | – | – | +204.8% | – | |
| Profit growth | – | +319.6% | -115.0% | – | – | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +45.5% | – | – |
| Net profit | +23.2% | – | – |
| EPS | 0.0% | – | – |
| Share price | – | -54.7% (2y) | -71.8% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 92 | 99 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 2 | 0 |
| Total assets | 92 | 99 |
| Fixed assets | 0 | 0 |
| Capital work in progress | 0 | 0 |
| Investments | 24 | 33 |
| Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Payables | 0 | 0 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | -1 | 2 |
| Cash from investing | -33 | -10 |
| Cash from financing | 36 | 6 |
| Capex | 0 | 0 |
| Free cash flow | -1 | 2 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | -0.3% | 0.9% |
| ROCE % | -0.3% | 1.0% |
| Debtor days | 0 | 0 |
| Inventory days | 0 | 0 |
| Payable days | 0 | 0 |
| Cash conversion cycle (days) | 0 | 0 |
| Working capital days | 1,117 | 39 |
Peers in Other Financial Services
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| ARCFIN | ₹37,47,491 cr | 43.0x | 37,875.8x | 0.8% | – | – | +66.4% | – |
| CRISIL | ₹34,926 cr | 39.5x | 10.7x | 29.1% | – | 29.8% | – | – |
| RRP | ₹10,960 cr | 1,406.3x | 1,211.9x | -60.1% | -47.5% | 105.2% | – | – |
| ARCIL | ₹3,972 cr | – | – | – | – | – | – | – |
| KISSHT | ₹3,472 cr | 6.5x | 2.6x | 21.0% | – | 29.9% | – | – |
| GYFTR | ₹1,229 cr | – | – | – | – | – | – | – |
| PRIMESECU | ₹929 cr | 35.5x | 4.4x | 13.2% | – | – | +23.5% | 0.54% |
| CENTRUM | ₹860 cr | – | 2.8x | -73.4% | – | – | +42.1% | – |
| REGENCY | ₹565 cr | 23.9x | 3.0x | 14.1% | – | – | +277.6% | – |
| BIOGEN | ₹25 cr | 12.0x | 0.3x | -0.2% | -0.2% | -59.1% | +45.5% | – |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Financial Services |
| Industry | Other Financial Services |
| Sub-industry | Other Financial Services |
| Symbol | BIOGEN |
| BSE code | 531752 |
| ISIN | INE703D01023 |
| Face value | ₹1.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.